Cellular Therapies in Acute Lymphoblastic Leukemia Journal Article


Authors: Park, J. H.; Sauter, C.; Brentjens, R.
Article Title: Cellular Therapies in Acute Lymphoblastic Leukemia
Abstract: Most adult patients with acute lymphoblastic leukemia (ALL) will die of the disease. The prognosis in all patients with relapsed or refractory disease is uniformly poor. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a related donor offers significant benefit for some patients, most lack a suitable related donor. Therefore, alternative approaches, including unrelated, umbilical cord blood, and haploidentical allo-HSCT, are being studied. Reduced-intensity conditioning further extends access to allo-HSCT for older more-comorbid patients. Modified adoptive T-cell regimens, including infusion of enriched tumor-targeted donor and genetically targeted autologous T cells, and natural killer cells genetically modified to target ALL are under investigation. © 2011 Elsevier Inc.
Keywords: cancer chemotherapy; cancer survival; overall survival; fludarabine; review; disease free survival; antineoplastic agent; animals; imatinib; quality of life; cyclophosphamide; hematopoietic stem cell transplantation; dasatinib; chronic myeloid leukemia; acute lymphoblastic leukemia; protein tyrosine kinase inhibitor; acute graft versus host disease; chronic graft versus host disease; myeloablative conditioning; reduced intensity conditioning; transplantation conditioning; chimeric antigen receptor; donor lymphocyte infusion; allogeneic hematopoietic stem cell transplantation; cell therapy; natural killer cell; adoptive transfer; precursor cell lymphoblastic leukemia-lymphoma; nilotinib; chronic lymphatic leukemia; graft versus leukemia effect; autologous hematopoietic stem cell transplantation; single chain fragment variable antibody; cell transplantation; leukemia remission; adoptive cellular therapy; hematopoietic stem cell transplants
Journal Title: Hematology/Oncology Clinics of North America
Volume: 25
Issue: 6
ISSN: 0889-8588
Publisher: Elsevier Inc.  
Date Published: 2011-12-01
Start Page: 1281
End Page: 1301
Language: English
DOI: 10.1016/j.hoc.2011.09.015
PROVIDER: scopus
PUBMED: 22093587
PMCID: PMC3551618
DOI/URL:
Notes: --- - "Export Date: 9 December 2011" - "CODEN: HCNAE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Jae Hong Park
    356 Park
  3. Craig Steven Sauter
    334 Sauter